Royalty Pharma Total Current Assets decreased by 6.7% to $1.43B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 22.6%, from $1.84B to $1.43B. Over 5 years (FY 2020 to FY 2025), Total Current Assets shows a downward trend with a -10.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher levels indicate stronger short-term liquidity, though excessive levels may suggest inefficient capital allocation.
The sum of all assets that are expected to be converted into cash or consumed within one year. This provides a snapshot...
Compared against current liabilities to determine the current ratio, a standard measure of short-term financial health.
total_current_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.71B | $2.78B | $2.88B | $2.98B | $3.50B | $2.34B | $2.55B | $2.63B | $2.95B | $1.73B | $1.27B | $1.56B | $2.58B | $1.79B | $1.80B | $1.84B | $1.52B | $1.85B | $1.53B | $1.43B |
| QoQ Change | — | +2.5% | +3.7% | +3.6% | +17.5% | -33.2% | +9.1% | +3.0% | +12.2% | -41.5% | -26.3% | +22.4% | +65.4% | -30.4% | +0.4% | +2.3% | -17.5% | +21.7% | -17.4% | -6.7% |
| YoY Change | — | — | — | — | +29.4% | -15.6% | -11.2% | -11.8% | -15.7% | -26.2% | -50.1% | -40.7% | -12.7% | +3.8% | +41.4% | +18.2% | -41.1% | +3.1% | -15.2% | -22.6% |